Shares Spectrum Pharmaceuticals (NASDAQ:SPPI) are plunging in today’s trading after scientists from the U.S. Food and Drug Administration (FDA) raised concerns over the data shared by the company for poziotinib for the treatment of non-small cell lung cancer (NSCLC).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
While the meeting of the advisory committee is scheduled for later this week, scientists from the regulator have flagged a low overall response rate as indicated by the data.
Moreover, concerns remain about dosage optimization and the safety profile of the drug as well.
Read full Disclosure